Beryl Leirvaag's picture

Beryl Leirvaag

Head Engineer
  • E-mailBeryl.Leirvaag@uib.no
  • Phone+47 55 97 64 44
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2020). Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Annals of Oncology. 1-10.
  • Show author(s) (2016). Prevalence of the CHEK2 R95* germline mutation. Hereditary Cancer in Clinical Practice. 4 pages.
  • Show author(s) (2015). Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. Molecular Oncology. 1553-1564.
  • Show author(s) (2012). Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Research. 12 pages.

More information in national current research information system (CRIStin)